Immunovant Inc (IMVT)

Name: Immunovant Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$0.0

Net Income

-$111M

Operating Margin

N/A

Free Cash Flow

-$377M

Debt / Assets

8.9%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Immunovant Inc (IMVT).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Revenue	0	0	0	160,000
Cost of Revenue	101,000	105,000	0	80,000
Gross Profit	-101,000	-105,000	0	80,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	15,438,000	17,513,000	26,024,000	20,254,000
Operating Expenses	114,362,000	131,762,000	127,224,000	113,906,000
Operating Income	-114,362,000	-131,762,000	-127,224,000	324,326,000
Interest Expense	0	0	0	0
Income Before Tax	-109,083,000	-125,908,000	-119,700,000	-105,865,000
Income Tax Expense	1,552,000	594,000	913,000	584,000
Net Income	-110,635,000	-126,502,000	-120,613,000	-106,449,000
Per Share
EPS	-0.61	-0.73	-0.71	-0.63
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Immunovant Inc (IMVT).
Income Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Revenue	0	0	0	0	0
Cost of Revenue	0	231,000	1,324,000	1,232,000	0
Gross Profit	0	-231,000	-1,324,000	-1,232,000	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	77,235,000	57,281,000	48,019,000	54,225,000	39,513,000
Operating Expenses	438,152,000	282,709,000	208,276,000	156,033,000	108,117,000
Operating Income	-438,152,000	-282,709,000	-198,469,000	-156,159,000	-108,117,000
Interest Expense	0	0	12,482,000	655,000	0
Income Before Tax	-412,949,000	-258,769,000	-210,951,000	-156,814,000	-107,789,000
Income Tax Expense	891,000	567,000	9,000	-84,000	-358,000
Net Income	-413,840,000	-259,336,000	-210,960,000	-156,730,000	-107,431,000
Per Share
EPS	-2.73	-1.88	-1.71	-1.43	-1.22
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Immunovant Inc (IMVT).
Balance Sheet (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Assets
Cash and Cash Equivalents	713,971,000	635,365,000	376,532,000	493,817,000
Short Term Investments	0	0	0	0
Net Receivables	2,511,000	5,503,000	885,000	12,861,000
Inventory	0	0	0	0
Total Current Assets	767,662,000	665,770,000	404,333,000	512,931,000
Property Plant Equipment	942,000	595,000	1,505,000	2,633,000
Goodwill and Intangibles	0	0	0	0
Total Assets	776,222,000	666,365,000	405,838,000	515,564,000
Liabilities
Account Payables	17,656,000	7,155,000	1,353,000	18,629,000
Short Term Debt	98,000	138,000	1,173,000	1,145,000
Total Current Liabilities	68,775,000	48,608,000	43,297,000	44,520,000
Long Term Debt	0	0	47,000	1,219,000
Total Liabilities	68,775,000	48,608,000	43,344,000	45,739,000
Shareholders Equity
Retained Earnings	-1,239,523,000	-825,683,000	-566,347,000	-355,387,000
Total Shareholders Equity	707,447,000	617,757,000	362,494,000	469,825,000

Balance sheet annual history for Immunovant Inc (IMVT).
Balance Sheet (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Assets
Cash and Cash Equivalents	713,971,000	635,365,000	376,532,000	493,817,000	400,146,000
Short Term Investments	0	0	0	0	0
Net Receivables	2,511,000	5,503,000	885,000	12,861,000	548,000
Inventory	0	0	0	0	0
Total Current Assets	767,662,000	665,770,000	404,333,000	512,931,000	409,006,000
Property Plant Equipment	942,000	595,000	1,505,000	2,633,000	3,483,000
Goodwill and Intangibles	0	0	0	0	0
Total Assets	776,222,000	666,365,000	405,838,000	515,564,000	412,489,000
Liabilities
Account Payables	17,656,000	7,155,000	1,353,000	18,629,000	2,432,000
Short Term Debt	98,000	138,000	1,173,000	1,145,000	1,179,000
Total Current Liabilities	68,775,000	48,608,000	43,297,000	44,520,000	18,771,000
Long Term Debt	0	0	47,000	1,219,000	2,238,000
Total Liabilities	68,775,000	48,608,000	43,344,000	45,739,000	21,009,000
Shareholders Equity
Retained Earnings	-1,239,523,000	-825,683,000	-566,347,000	-355,387,000	-198,657,000
Total Shareholders Equity	707,447,000	617,757,000	362,494,000	469,825,000	391,480,000

Cash flow quarterly history for Immunovant Inc (IMVT).
Cash Flow Statement (Quarterly)	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Operating Activities
Net Income	-413,840,000	-259,336,000	-210,960,000	-156,730,000
Depreciation & Amortization	377,000	231,000	193,000	126,000
Stock Based Compensation	49,487,000	41,116,000	32,296,000	34,244,000
Change in Working Capital	-12,031,000	2,632,000	-10,853,000	15,142,000
Operating Cash Flow	-375,874,000	-214,227,000	-188,193,000	-106,112,000
Investing Activities
Capital Expenditure	-759,000	-360,000	-197,000	-254,000
Investments	-759,000	-360,000	-197,000	-254,000
Investing Cash Flow	-759,000	-360,000	-197,000	-254,000
Financing Activities
Debt Repayment	0	0	0	0
Common Stock Issued/Repurchased	450,000,000	472,745,000	70,500,000	129,000
Dividends Paid	0	0	0	0
Financing Cash Flow	454,492,000	472,427,000	70,885,000	200,129,000
Summary
Free Cash Flow	-376,633,000	-214,587,000	-188,390,000	-106,366,000
Net Change in Cash	78,606,000	258,833,000	-117,285,000	93,671,000

Cash flow annual history for Immunovant Inc (IMVT).
Cash Flow Statement (Annual)	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Operating Activities
Net Income	-413,840,000	-259,336,000	-210,960,000	-156,730,000	-107,431,000
Depreciation & Amortization	377,000	231,000	193,000	126,000	65,000
Stock Based Compensation	49,487,000	41,116,000	32,296,000	34,244,000	18,822,000
Change in Working Capital	-12,031,000	2,632,000	-10,853,000	15,142,000	4,566,000
Operating Cash Flow	-375,874,000	-214,227,000	-188,193,000	-106,112,000	-83,327,000
Investing Activities
Capital Expenditure	-759,000	-360,000	-197,000	-254,000	-210,000
Investments	-759,000	-360,000	-197,000	-254,000	-210,000
Investing Cash Flow	-759,000	-360,000	-197,000	-254,000	-210,000
Financing Activities
Debt Repayment	0	0	0	0	-3,190,000
Common Stock Issued/Repurchased	450,000,000	472,745,000	70,500,000	129,000	319,783,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	454,492,000	472,427,000	70,885,000	200,129,000	383,112,000
Summary
Free Cash Flow	-376,633,000	-214,587,000	-188,390,000	-106,366,000	-83,537,000
Net Change in Cash	78,606,000	258,833,000	-117,285,000	93,671,000	299,575,000